Attached files
| file | filename |
|---|---|
| EX-10.25 - EXHIBIT 10.25 - Zander Therapeutics, Inc | ex10_25.htm |
| 10-K - FORM 10-K - Zander Therapeutics, Inc | zander063018form10k.htm |
| EX-32.2 - EXHIBIT 32.2 - Zander Therapeutics, Inc | ex32_2.htm |
| EX-31.2 - EXHIBIT 31.2 - Zander Therapeutics, Inc | ex31_2.htm |
| EX-31.1 - EXHIBIT 31.1 - Zander Therapeutics, Inc | ex31_1.htm |
| EX-10.26 - EXHIBIT 10.26 - Zander Therapeutics, Inc | ex10_26.htm |
| EX-10.24 - EXHIBIT 10.24 - Zander Therapeutics, Inc | ex10_24.htm |
| EX-10.23 - EXHIBIT 10.23 - Zander Therapeutics, Inc | ex10_23.htm |
| EX-10.22 - EXHIBIT 10.22 - Zander Therapeutics, Inc | ex10_22.htm |
| EX-10.21 - EXHIBIT 10.21 - Zander Therapeutics, Inc | ex10_21.htm |
| EX-10.14 - EXHIBIT 10.14 - Zander Therapeutics, Inc | ex10_14.htm |
| EX-10.13 - EXHIBIT 10.13 - Zander Therapeutics, Inc | ex10_13.htm |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Zander Therapeutics, Inc. on Form 10-K for the year ended June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David R. Koos, Chief Executive Officer certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: 9/25/2018 | By: | /s/ David R. Koos |
| David R. Koos | ||
| Chief Executive Officer | ||